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Purpose
To investigate the adverse event (AE) rates associated
with natural health product (NHP) use, prescription
drug use and concurrent NHPs-drug use through active
surveillance in community pharmacies in Alberta and
British Columbia, Canada.
Methods
Participating pharmacists and pharmacy technicians
screened consecutive individuals picking up prescription
medications about their (1) NHP use, (2) prescription
medication use, (3) concurrent NHP/prescription medica-
tion use in the previous one month, and (4) the occur-
rence of potential AEs. If a potential AE was identified and
the patient provided written consent, a research pharma-
cist conducted a guided telephone interview to gather
additional detailed information on the AE and medical
history of the patient.
Results
Over a total of 105 pharmacy weeks, 1119 patients were
screened. Of these patients, 409 reported taking prescrip-
tion drugs only (36%; 95% CI: 33.7-39.4), 41 reported tak-
ing NHPs only (3.7%; 95% CI: 2.6-4.8) and 656 reported
taking NHPs and prescription medication concurrently
(58.6%; 95% CI: 55.7 to 61.5). A total of 58 patients
reported a possible AE, which represents 0.98% (95% CI:
0.03 to 1.93) of those taking prescription medications only,
9.8% of those taking NHPs only (95% CI: 0.7% to 18.9) and
7.5% of those taking NHPs and prescription medications
concurrently (95% CI: 5.48 to 9.52).
Conclusion
Compared to passive surveillance, this study found active
surveillance to markedly improve NHP adverse event
reporting rates. Active surveillance offers improved quan-
tity and quality of adverse event data, allowing for mean-
ingful adjudication to assess potential harms.
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